At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12,210 enrolled
Drug / intervention
Early CDT Lung blood testbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung Test
In Brief
A clinical study evaluating Early CDT Lung blood test for Lung Cancer. Completed, enrolled 12,210 participants across 3 sites.
Detailed Summary
HYPOTHESIS In a high risk population the EarlyCDT-Lung test reduces the incidence of late stage tumours;3 / 4 / Unclassified (U) at diagnosis compared to normal clinical practice.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedAug 2013
Primary CompletionAug 2018
TodayJul 2026
First PostedAug 20, 2013
Enrollment StartAug 1, 2013
Primary CompletionAug 31, 2018
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 12.9 years ago
Interventions
Early CDT Lung blood testbiological
The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.